Market Cap 20.03B
Revenue (ttm) 3.25B
Net Income (ttm) -207.95M
EPS (ttm) N/A
PE Ratio 2,598.00
Forward PE 61.35
Profit Margin -6.40%
Debt to Equity Ratio 0.00
Volume 21,562,100
Avg Vol 2,640,294
Day's Range N/A - N/A
Shares Out 190.89M
Stochastic %K 96%
Beta 1.41
Analysts Sell
Price Target $101.44

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Te...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 608 284 5700
Address:
5505 Endeavor Lane, Madison, United States
DoctrBenway
DoctrBenway May. 12 at 1:40 PM
$GERN Uptake takes time. Stay long and the numbers continually become more compelling as hematologists (prone to inertia until something is proven compellingly better) change their practice in MDS/MF. Analogy: I knew Cologuard would have uptake and bought tons of $EXAS in the $4 range, I knew low risk patients would eschew a prep and procedure once the diagnostic follow-up was covered.
0 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro May. 8 at 7:14 PM
$ABT $EXAS and poor leadership killed this. Not recovering any time soon
0 · Reply
malphius
malphius May. 8 at 6:17 PM
$EXAS Did you know there is an overlap with $HUMA and the board of directors? Did you know that 1 share of EXAS will buy 100 shares of $HUMA right before their June 11 V012 Phase 3 catalyst to unlock the Dialysis market?
1 · Reply
Stockprofiler
Stockprofiler May. 6 at 4:57 PM
$VNRX New Article. VolitionRx is stacking catalysts heading into Q4 2026 — finger-prick sepsis detection, French reimbursement, a $5M vet milestone, and licensing talks with 10 major diagnostics players. Revenue up 40%. Not financial advice. DYOR. https://allcapresearch.com/f/volitionrx-vnrx-stacking-catalysts-into-q4-2026 $EXAS $ILMN $PACB $NTRA
1 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro May. 5 at 1:56 PM
$ABT Grossly overpaid for $EXAS . Now employees and shareholders suffer. Do something leadership!!!!
1 · Reply
FundaTech
FundaTech May. 1 at 6:44 PM
$ABT The acquisition of $EXAS was a very good strategic deal that refreshes its diagnostics story and bets on secular tailwinds in oncology/prevention. Near-term pain (dilution, stock reaction) is typical for large accretive-over-time acquisitions, but the +3B sales addition and margin/synergy upside support long-term value if integration succeeds. Many analysts see it enhancing Abbott’s growth profile.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 29 at 11:17 AM
$NEO $EXAS $GH $NTRA $NEO move is no pump n dump — this is what a real fundamental breakout looks like. 🚀 NEO ripping premarket is a direct reaction to legit catalysts, not hype: 🔥 Q1 Earnings Beat • Revenue came in at $187M, beating Wall Street • Clinical revenue up 14% YoY • High-margin NGS revenue exploded 26% • Management RAISED 2026 guidance to $797M$803M 🔥 Analyst Upgrades Rolling In • Leerink upgraded to Outperform and doubled PT from $12 to $25 • Benchmark also upgraded to Buy 🔥 MolDX Approval PanTracer liquid biopsy getting reimbursement support is a game changer — opens the door for recurring revenue and lowers risk big time. 💰 Heavy volume + better numbers + raised guidance + analysts chasing = smart money stepping in. This isn’t a pump… this is institutions repricing NEO higher. 📈
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 17 at 5:19 AM
LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff? $LCID $ABT $ASBP $EXAS https://stocktwits.com/news/equity/markets/why-lcid-abt-asbp-stocks-hit-52-week-lows-today/cZJUhKPRIxB
0 · Reply
WycklyTrader
WycklyTrader Apr. 2 at 4:17 AM
KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.
0 · Reply
CromieAds
CromieAds Apr. 1 at 1:46 PM
0 · Reply
Latest News on EXAS
Exact Sciences Stockholders Approve Acquisition by Abbott

Feb 20, 2026, 4:05 PM EST - 2 months ago

Exact Sciences Stockholders Approve Acquisition by Abbott

ABT


Abbott to Acquire Exact Sciences for $21 Billion

Nov 20, 2025, 7:46 AM EST - 6 months ago

Abbott to Acquire Exact Sciences for $21 Billion

ABT


Exact Sciences to Participate in November Investor Conference

Nov 4, 2025, 7:00 AM EST - 6 months ago

Exact Sciences to Participate in November Investor Conference


Exact Sciences Announces Third Quarter 2025 Results

Nov 3, 2025, 4:05 PM EST - 6 months ago

Exact Sciences Announces Third Quarter 2025 Results


Exact Sciences Schedules Third Quarter 2025 Earnings Call

Oct 8, 2025, 7:00 AM EDT - 7 months ago

Exact Sciences Schedules Third Quarter 2025 Earnings Call


Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Sep 15, 2025, 3:30 PM EDT - 8 months ago

Exact Sciences CEO on Launch of Multi-Cancer Blood Test


Exact Sciences to Participate in September Investor Conferences

Aug 19, 2025, 6:00 AM EDT - 9 months ago

Exact Sciences to Participate in September Investor Conferences


Exact Sciences Announces Second Quarter 2025 Results

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Exact Sciences Announces Second Quarter 2025 Results


Exact Sciences Schedules Second Quarter 2025 Earnings Call

Jul 14, 2025, 6:00 AM EDT - 10 months ago

Exact Sciences Schedules Second Quarter 2025 Earnings Call


Exact Sciences to Participate in June Investor Conference

May 27, 2025, 4:05 PM EDT - 1 year ago

Exact Sciences to Participate in June Investor Conference


DoctrBenway
DoctrBenway May. 12 at 1:40 PM
$GERN Uptake takes time. Stay long and the numbers continually become more compelling as hematologists (prone to inertia until something is proven compellingly better) change their practice in MDS/MF. Analogy: I knew Cologuard would have uptake and bought tons of $EXAS in the $4 range, I knew low risk patients would eschew a prep and procedure once the diagnostic follow-up was covered.
0 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro May. 8 at 7:14 PM
$ABT $EXAS and poor leadership killed this. Not recovering any time soon
0 · Reply
malphius
malphius May. 8 at 6:17 PM
$EXAS Did you know there is an overlap with $HUMA and the board of directors? Did you know that 1 share of EXAS will buy 100 shares of $HUMA right before their June 11 V012 Phase 3 catalyst to unlock the Dialysis market?
1 · Reply
Stockprofiler
Stockprofiler May. 6 at 4:57 PM
$VNRX New Article. VolitionRx is stacking catalysts heading into Q4 2026 — finger-prick sepsis detection, French reimbursement, a $5M vet milestone, and licensing talks with 10 major diagnostics players. Revenue up 40%. Not financial advice. DYOR. https://allcapresearch.com/f/volitionrx-vnrx-stacking-catalysts-into-q4-2026 $EXAS $ILMN $PACB $NTRA
1 · Reply
Enjoy_Life_Bro
Enjoy_Life_Bro May. 5 at 1:56 PM
$ABT Grossly overpaid for $EXAS . Now employees and shareholders suffer. Do something leadership!!!!
1 · Reply
FundaTech
FundaTech May. 1 at 6:44 PM
$ABT The acquisition of $EXAS was a very good strategic deal that refreshes its diagnostics story and bets on secular tailwinds in oncology/prevention. Near-term pain (dilution, stock reaction) is typical for large accretive-over-time acquisitions, but the +3B sales addition and margin/synergy upside support long-term value if integration succeeds. Many analysts see it enhancing Abbott’s growth profile.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 29 at 11:17 AM
$NEO $EXAS $GH $NTRA $NEO move is no pump n dump — this is what a real fundamental breakout looks like. 🚀 NEO ripping premarket is a direct reaction to legit catalysts, not hype: 🔥 Q1 Earnings Beat • Revenue came in at $187M, beating Wall Street • Clinical revenue up 14% YoY • High-margin NGS revenue exploded 26% • Management RAISED 2026 guidance to $797M$803M 🔥 Analyst Upgrades Rolling In • Leerink upgraded to Outperform and doubled PT from $12 to $25 • Benchmark also upgraded to Buy 🔥 MolDX Approval PanTracer liquid biopsy getting reimbursement support is a game changer — opens the door for recurring revenue and lowers risk big time. 💰 Heavy volume + better numbers + raised guidance + analysts chasing = smart money stepping in. This isn’t a pump… this is institutions repricing NEO higher. 📈
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 17 at 5:19 AM
LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff? $LCID $ABT $ASBP $EXAS https://stocktwits.com/news/equity/markets/why-lcid-abt-asbp-stocks-hit-52-week-lows-today/cZJUhKPRIxB
0 · Reply
WycklyTrader
WycklyTrader Apr. 2 at 4:17 AM
KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.
0 · Reply
CromieAds
CromieAds Apr. 1 at 1:46 PM
0 · Reply
CromieAds
CromieAds Mar. 31 at 11:44 PM
$CAI should run up nicely tomorrow. This is big news!… https://www.prnewswire.com/news-releases/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-302730659.html $EXAS $GH $GRAL
1 · Reply
thingkfast
thingkfast Mar. 27 at 1:33 PM
$EXAS well I’m officially taking EXAS off my watchlist, what a ride it has been. Our flagship products are now in the hands of Abbott with worldwide reach and exposure!! It was great talking to everyone. Remember Freenome is going public under FRNM in the first half of this year!! Good luck to all
0 · Reply
julianjakobi
julianjakobi Mar. 25 at 4:34 PM
Big congrats to everyone in $EXAS — insane run. A lot of us saw ~2000% gains, which honestly doesn’t happen often. I’ve personally rotated almost $ 1/2 Million of that into $BLGO. Different stage, but similar kind of setup in my opinion. Their Clyra Medical subsidiary is working on what could become a real game-changer in wound care with this copper-iodine tech. They’ve already locked in a deal with one of the top 4 medical companies, and from what I understand, products should hit the market this year once packaging clears. Manufacturing is ready for at least 2M units annually, so this isn’t some early concept anymore. The first product - ViaClyr - is just starting to roll out, and the bigger surgical push is expected later this year. Feels like one of those situations where the market hasn’t caught up yet. Definitely worth digging into if you’re looking for the next move post-EXAS. $EXAS $BLGO Check out what a woundcare specialist had to say in the photos attached.
3 · Reply
Easternbikes5
Easternbikes5 Mar. 25 at 1:23 PM
$EXAS guess my 4/17 calls for 105 are done. Originally seen the merger close in q2, $250 loss.
0 · Reply
FoolsInLove
FoolsInLove Mar. 25 at 3:26 AM
$EXAS im still waiting for the competitive bid from Pfizer…
0 · Reply
Gilgamesh
Gilgamesh Mar. 24 at 5:38 PM
$EXAS @Serafina1991 If you sella lot of $EXAS at a loss you can’t buy back within 30 days or you can’t take the tax loss. Buying a different biotech stock is not a problem-you can take the loss. Me lawyer.
0 · Reply
katico
katico Mar. 24 at 2:55 PM
$EXAS wash sales would be triggered by purchases of what the IRS considers **like-kind** investments. This means if you are selling EXAS (or any share lots within your EXAS overall investment) at a loss, and you want to avoid a wash sale, you should not purchase another biotech stock for 31 days after the EXAS sale. The same would apply to any biotech purchases made 30 days prior to the EXAS sale. Hope this helps!
1 · Reply
30DeltaSpy
30DeltaSpy Mar. 23 at 7:04 PM
$ABT + $EXAS Abbott closes $21B Exact Sciences deal https://www.chicagobusiness.com/health-care/ccb-abbott-exact-sciences-deal-closes/?utm_content=article8-headline&utm_source=afternoon-10&utm_medium=email&utm_campaign=20260323
0 · Reply
Serafina1991
Serafina1991 Mar. 23 at 6:07 PM
$EXAS I would love to hear from other EXAS Investors who will have all of their shares purchased today/tomorrow. Overall, I will be seeing a nice long term gain but there are some lots (long loss) pockets that will be offsetting some of those profits. Will those losses within my overall profit from EXAS shares be considered a basis for a wash sale should I decide to purchase another Biotech's shares within 31 days? I know that Is how It usually works but I AM realizing an overall profit from the sale of all of my EXAS shares and It IS a buyout. Thanks for the anticipated discussion
2 · Reply
bearcreekzeke
bearcreekzeke Mar. 23 at 4:58 PM
$EXAS Farewell and best of luck to you all my friends! One last Reddit post for you all. Please feel free to stop by and leave a comment - https://www.reddit.com/r/exactsciences/comments/1s1mbwy/exact_sciences_is_now_abbott/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
0 · Reply
bearcreekzeke
bearcreekzeke Mar. 23 at 4:55 PM
$EXAS For old time's sake: https://youtu.be/J2hI3-KvYZY?si=61TDSgT_-kAQQzV0
0 · Reply
Gilgamesh
Gilgamesh Mar. 23 at 3:17 PM
$EXAS Anyone get their money yet? Still waiting.
1 · Reply